Citigroup began coverage on shares of Tocagen (NASDAQ:TOCA) in a report published on Tuesday morning, Marketbeat.com reports. The brokerage issued a buy rating and a $27.00 target price on the stock.

A number of other analysts have also issued reports on TOCA. Zacks Investment Research lowered Tocagen from a strong-buy rating to a hold rating in a research note on Wednesday, May 9th. B. Riley started coverage on Tocagen in a research note on Wednesday, May 16th. They issued a buy rating and a $15.00 price target on the stock. HC Wainwright started coverage on Tocagen in a research note on Monday, June 11th. They issued a buy rating and a $14.50 price target on the stock. LADENBURG THALM/SH SH started coverage on Tocagen in a research note on Wednesday, June 27th. They issued a buy rating and a $20.00 price target on the stock. Finally, ValuEngine raised Tocagen from a sell rating to a hold rating in a research note on Monday, July 2nd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus target price of $19.58.

Shares of NASDAQ:TOCA opened at $11.05 on Tuesday. The company has a current ratio of 6.06, a quick ratio of 6.06 and a debt-to-equity ratio of 0.56. The company has a market capitalization of $227.04 million, a PE ratio of -4.15 and a beta of 2.29. Tocagen has a 1 year low of $7.52 and a 1 year high of $14.66.

Tocagen (NASDAQ:TOCA) last issued its quarterly earnings results on Tuesday, August 7th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.56) by ($0.25). The firm had revenue of $0.01 million during the quarter, compared to analyst estimates of $2.01 million. Tocagen had a negative return on equity of 77.46% and a negative net margin of 130,944.75%. research analysts anticipate that Tocagen will post -2.67 EPS for the current fiscal year.

Institutional investors have recently made changes to their positions in the stock. Russell Investments Group Ltd. lifted its position in Tocagen by 107.4% during the first quarter. Russell Investments Group Ltd. now owns 81,067 shares of the company’s stock worth $961,000 after buying an additional 41,978 shares in the last quarter. Wells Fargo & Company MN lifted its position in Tocagen by 100.2% during the fourth quarter. Wells Fargo & Company MN now owns 31,698 shares of the company’s stock worth $325,000 after buying an additional 15,862 shares in the last quarter. Deutsche Bank AG lifted its position in Tocagen by 472.5% during the fourth quarter. Deutsche Bank AG now owns 43,060 shares of the company’s stock worth $440,000 after buying an additional 35,539 shares in the last quarter. TIAA CREF Investment Management LLC lifted its position in Tocagen by 58.4% during the fourth quarter. TIAA CREF Investment Management LLC now owns 35,994 shares of the company’s stock worth $369,000 after buying an additional 13,267 shares in the last quarter. Finally, Rhumbline Advisers purchased a new position in Tocagen during the first quarter worth approximately $178,000. Hedge funds and other institutional investors own 28.12% of the company’s stock.

About Tocagen

Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells.

See Also: Hedge Funds – How They Work For Investors

Analyst Recommendations for Tocagen (NASDAQ:TOCA)

Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.